Heron Therapeutics (NASDAQ:HRTX) Rating Reiterated by Needham & Company LLC

Heron Therapeutics (NASDAQ:HRTX)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued on Wednesday, Benzinga reports. They currently have a $5.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target suggests a potential upside of 74.22% from the stock’s previous close.

HRTX has been the topic of several other reports. StockNews.com upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Capital One Financial started coverage on Heron Therapeutics in a report on Tuesday, April 23rd. They issued an “overweight” rating and a $6.00 target price for the company.

Heron Therapeutics Stock Performance

Shares of NASDAQ HRTX opened at $2.87 on Wednesday. The business has a 50 day simple moving average of $2.72 and a 200 day simple moving average of $2.08. Heron Therapeutics has a 52 week low of $0.50 and a 52 week high of $3.22. The stock has a market cap of $432.33 million, a price-to-earnings ratio of -3.34 and a beta of 1.73.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.08. The business had revenue of $34.23 million during the quarter, compared to the consensus estimate of $30.98 million. On average, analysts predict that Heron Therapeutics will post -0.24 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC bought a new position in shares of Heron Therapeutics in the first quarter worth about $30,000. SG Americas Securities LLC bought a new position in shares of Heron Therapeutics during the 3rd quarter worth about $31,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Heron Therapeutics during the 1st quarter valued at about $32,000. Victory Capital Management Inc. increased its stake in Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 4,617 shares during the period. Finally, ACT Advisors LLC. bought a new stake in Heron Therapeutics in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.